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Oral Abstract Session 1: Rhinitis
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Mayorga, Luisa Galindo, Ana Molina, Miguel Blanca, Maria Jose Torres
Hospital Regional Universitario de Malaga and IBIMA, Málaga, Spain 
Correspondence: Ibon Eguiluz Gracia - iboneguiluz@gmail.com
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Introduction: There are few data available regarding natural history 
of local allergic rhinitis (LAR). We previously reported the results of 
the first 5-years of follow-up observing a similar rate of development 
of systemic allergic rhinitis (AR) in both LAR patients and healthy 
controls.
Objective: To explore the natural history of a population with LAR and 
the development of AR and comorbidities over a 10 year period.
Methods: A cohort of 194 patients with LAR of recent onset 
(<18  months) and 130 age- and sex-matched healthy controls were 
prospectively evaluated in a 10-year follow-up study (2005–2016). All 
participants provided informed consent and ethic committee of the 
hospital approved the study. Clinical-demographic questionnaire, 
spirometry, SPT and specific IgE (sIgE) to aeroallergens were evaluated 
yearly. Nasal allergen provocation tests (NAPT) with D. pteronyssinus 
(DP), Alternaria, Olea europea, and grass pollen were performed at 
baseline, and after 5 and 10 years.
Results: A total of 151 patients (78%) and 90 controls (69%) com-
pleted the study. At baseline, most patients had moderate-to-
severe persistent-perennial rhinitis. Conjunctivitis (52%) and 
asthma (19%) were the main comorbidities, and DP the most fre-
quent sensitizing aeroallergen (51.1%). During the 10 years of eval-
uation 21 new cases of asthma (12.5%, P = 0.007) and 17 new cases 
of conjunctivitis (10%, P  =  0.067) were diagnosed. After 10  years 
of evolution a similar rate of development of AR was detected in 
patients and healthy controls (11.3 vs 10%, P = 0.761). In 5 patients, 
conversion to systemic atopy occurred in the last year of evaluation 
(3%).
Conclusions: LAR is a well-differentiated clinical entity with a low 
rate of development of systemic atopy. This study was funded by the 
Institute of Health “Carlos III” of the Spanish Ministry of Economy and 
Competitiveness through the RETICS ARADyAL (RD16/0006/0001) and 
the FIS PI14/00864.
Keywords: Local allergic rhinitis, Allergic rhinitis, Sensitization
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ILC2‑activation aggravates Th2‑dependent nasal inflammation 
in mice
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Introduction: It is well known that T helper (Th) 2 cells and group 2 
innate lymphoid cells (ILC2s) contribute to allergic diseases. However, 
their exact role and relationship in nasal allergic disorders is unclear. 
We sought to investigate the cooperation of Th2 cells and ILC2s in a 
mouse model of nasal allergic disorder.
Methods: To differentially activate Th2 cells and/or ILC2s in nasal 
mucosa, mice were intranasally administered ovalbumin (OVA) anti-
gen, papain, an ILC2-activatior, or both for 2 weeks. Epithelial thickness 
and number of eosinophils in the nasal mucosa were evaluated at 24 h 
after the final challenge.
Results: Intranasal administration of OVA and papain preferentially 
activated Th2 cells and ILC2s, respectively, in the nose. Both OVA 
and papain increased the nasal epithelial thickness and number of 
eosinophils, and their coadministration significantly enhanced the 
symptoms. ILC2- and Rag2-deficient mice showed a partial decrease 
in OVA-plus-papain-induced nasal epithelial thickening and eosino-
philia. Interleukin (IL)-33- and ST2-deficient mice showed decreased 
OVA-plus-papain-induced, but not OVA-alone-induced nasal epithelial 
thickening and eosinophilia. IL-5 induced eosinophilia only, but IL-13 
contributed to both nasal epithelial thickening and eosinophilia.
Conclusions: IL-33/ST2-pathway-mediated ILC2 activation exacer-
bated additively Th2-cell-induced nasal type 2 inflammation. Further-
more, IL-13, but not IL-5, contributes to exacerbation of nasal type 2 
inflammation.
Keywords: Nasal allergy, Th2 cells, Group 2 innate lymphoid cells, 
IL-33, IL-13
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O03 
Allergen endotoxins induce non‑IgE‑mediated nasal 
hypersensitivity in mice via monocyte/macrophage‑dependent 
pathway
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Hyogo College of Medicine, Nishinomiya, Japan 
Correspondence: Tomohiro Yoshimoto - tomo@hyo-med.ac.jp
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Introduction: Allergen-mediated cross-linking of IgE on mast cells/
basophils is a well-recognized trigger for type-1 allergic diseases such 
as allergic rhinitis (AR). However, allergens may not be the only trig-
ger for AR, and several allergic-like reactions are induced by non-IgE-
mediated mechanisms. Here, we describe a novel non-IgE-mediated, 
endotoxin-triggered nasal type-1-hypersensitivity reaction in mice.
Methods: To investigate whether endotoxin affects sneezing 
responses, mice were intraperitoneally immunized with ovalbumin 
(OVA), and then nasally challenged with endotoxin-free or endotoxin-
containing OVA. To investigate the role of T cells and mechanisms of 
the endotoxin-induced response, mice were adoptively transferred 
with in  vitro differentiated OVA-specific Th2 cells, and then nasally 
challenged with endotoxin-free or endotoxin-containing OVA. Imme-
diately after each nasal challenge, the frequency of sneezing was 
counted for 10 min. The mice were sacrificed 24 h after the final nasal 
challenge, and noses were dissected for analyzing infiltrating inflam-
matory cells.
Results: Endotoxin-containing, but not endotoxin-free, OVA elicited 
sneezing responses in mice independent from IgE-mediated signal-
ing. OVA-specific Th2 cell adoptive transfer to mice demonstrated 
that local activation of antigen-specific Th2 cells was required for 
the response. The Toll-like receptor 4-MyD 88-signaling pathway was 
indispensable for endotoxin-containing OVA-elicited rhinitis. In addi-
tion, lipopolysaccharide directly triggered sneezing responses in OVA-
specific Th2-transferred and nasally endotoxin-free OVA-primed mice. 
Although an antihistamine, diphenhydramine, suppressed sneezing 
responses, mast-cell/basophil-depleted mice had normal sneezing 
responses to endotoxin-containing OVA. Clodronate treatment abro-
gated endotoxin-containing OVA-elicited rhinitis, suggesting the 
involvement of monocytes/macrophages in this response.
Conclusions: Antigen-specific nasal activation of  CD4+ T cells followed 
by endotoxin exposure induces mast cell/basophil-independent hista-
mine release in the nose that elicits sneezing responses. Thus, environ-
mental or nasal residential bacteria may exacerbate AR symptoms. In 
addition, this novel phenomenon might explain currently unknown 
mechanisms in non–IgE-mediated allergic disorders, such as non-IgE-
mediated gastrointestinal food allergy in infants.
Keywords: Non-allergic rhinitis, Endotoxin, Histamine, T cells, 
Monocytes/macrophages
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Increased microbial abundance and decreased diversity 
in preschool children at risk for asthma
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Introduction: Recent studies suggest that a specific respiratory micro-
biome is associated with an increased risk of viral infection and that 
in turn these infections influence the composition of the resident 
microbiota. A commonly found virus that causes infection in preschool 
children is Rhinovirus (RV), wheeze is an important symptom. Children 
with a symptomatic RV infection have an increased risk to develop 
persistent wheeze and asthma.
If children with a RV infection have a specific respiratory microbiome 
this may hold implications for early diagnosis of asthma and novel 
therapeutic approaches aimed at restoring microbial dysbiosis.
Methods: We aimed to study this by comparing the nasal microbiome 
of children with physician confirmed wheeze, during acute symptoms 
and after recovery, to symptomatic controls with non-wheezing res-
piratory illness and asymptomatic healthy controls. Specificity of our 
outcomes for RV was determined by matched analysis in RV nega-
tive (RV-) children. As part of the EUROPA-study children were visited 
within 8 h of exhibiting respiratory symptoms and again upon recov-
ery for assessment of symptoms and nasal swab collection. Swabs 
were tested by qPCR for 14 respiratory viruses. Bacterial microbiota 
analysis was done by IS-pro, a 16S-23S PCR-based bacterial profiling 
technique. Relative abundance and Shannon diversity index were 
compared between groups.
Results: 160 pre-school children were included in the study. RV 
induced wheeze had the highest normalized total bacterial abun-
dance (mean ±  SEM; 0.95 ±  0.08) followed by symptomatic controls 
(0.77 ± 0.08) and asymptomatic controls (0.57 ± 0.09, p = 0.01). This 
increase was related to an upregulation of bacterial species belong-
ing to the phyla of Firmicutes and Bacteroidetes of which the latter 
persisted after recovery from infection. None of the control subjects 
carried Bacteroidetes. Microbial diversity was significantly (p  =  0.04) 
decreased in RV+ wheezing children (Median [IQR] 1.60 [0.97]) com-
pared to RV− wheezing children (2.00 [0.75]).
Conclusions: We established an increased microbial abundance and 
decreased microbial diversity in children with Rhinovirus induced 
wheeze who are at an increased risk to develop asthma. For a subset of 
these children this was primarily attributed to shifts in various species 
belonging to the phylum of Bacteroidetes. Our findings hold potential 
implications for the early diagnosis of asthma and novel therapeutic 
approaches aimed at restoring microbial dysbiosis.
Keywords: Asthma, Respiratory Microbiome, Rhinovirus, Wheeze, 
IS-Pro
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Proteomics of eosinophilic mucin
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Introduction: Eosinophilic mucin is a clinical relevant nasal secre-
tion in patients with chronic rhinosinusitis (CRS) warning the surgeon 
of increased risks of recurrence of both nasal polyps and symptoms. 
While the pathophysiology leading to this thick, glue-like mucus is 
poorly understood, physicians are increasingly confronted to employ 
topical and or systemic strategies to avoid postoperative deterioration. 
Aim of this study was to determine a typical proteomics signature of 
eosinophilic mucin to improve our understanding of the underlying 
pathophysiology.
Methods: Nasal secretions were collected from 10 healthy volunteers 
and compared to intraoperatively collected specimens of eosinophilic 
mucin. Pooled samples were analyzed using 2D-Gel PAGE, MALDI-MS 
and IPA analysis. Gender contributions was balanced and topical medi-
cation as well as allergy as confounding factors excluded.
Results: 593 proteins were identified, of which 373 proteins were pre-
sent in both pooled samples (mucin only 76, healthy lavage only 144 
proteins). 303 out of 393 proteins were regulated in their expression. 
If a cut-off value of 1.5 was determined, 43 were induced and 40 were 
reprimed in eosinophilic mucin.
Conclusions: Based on our results, specific proteomic changes could 
be observed in eosinophilic mucin enabling further insight into the 
specific pathophysiology leading to deterioration in this subgroup of 
CRS patients.
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Poster Discussion Session 1: Rhinitis
P01 
Probiotics impregnated bedding covers in house dust mite 
allergic rhinitis patients: a pilot randomized controlled trial
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Introduction: House dust mite exposure is a major cause of allergy 
worldwide. As current evidence for existing house dust mite avoid-
ance measures is low, new methods are being developed.
Objectives: To explore the effect of probiotics-impregnated bedding 
covers on symptoms and quality of life of patients with allergic rhinitis 
to house dust mite.
Methods: A double-blind, randomised, placebo-controlled, crossover 
trial was conducted at Ghent University Hospital, Belgium. The pilot 
trial included 20 adult patients with allergic rhinitis to house dust 
mite. The trial consisted of an 8-week period with untreated (placebo) 
covers and an 8-week period with probiotics-impregnated covers in 
random order, with a washout period in between of at least 4 weeks. 
Der p 1 concentrations were measured in dust samples collected from 
mattresses and pillows. Symptoms and quality of life were assessed 
through self-reported questionnaires.
Product information: The probiotics-based textile treatment con-
tains five different probiotic and natural bacterial strains of Bacil-
lus species (Bacillus subtilis, Bacillus amyloliquefaciens and Bacillus 
pumilus). The probiotics are incorporated in microcapsules, which 
are diffusely inserted in the textile. The probiotics remain non-
active in the closed microcapsules, until upon friction forces a small 
number of the microcapsules rupture and release their probiotic 
bacteria.
Results: There was a comparable and significant reduction of Der p 1 
levels with both the probiotics-impregnated covers and the untreated 
covers. Several symptom and quality of life scores improved signifi-
cantly with the probiotics-impregnated covers, whereas no significant 
changes were observed with the untreated covers. The effects of the 
probiotics-impregnated covers on symptoms and quality of life scores 
however were not significant compared to the placebo covers (except 
for a subscore ‘NRQLQ sleeptime’).
Conclusions: This pilot study suggests that probiotics-impregnated 
bedding covers may improve symptoms and quality of life of patients 
with allergic rhinitis to house dust mite. Although the effects of the 
probiotics-impregnated covers were not significant compared to the 
untreated covers, these findings are promising and warrant a future 
large-scale clinical trial.
Prior to patient enrolment, the trial was registered at clinical.trials.gov 
(NCT01997606).
Keywords: Allergy, Rhinitis, House dust mite, Probiotics, Avoidance
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of allergen microarray
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Introduction: In nasal secretions (NS) IgE is present at very low con-
centrations and difficult to detect with standard methods.
To evaluate the performance of a customized microarray chip (Thermo 
Fisher Scientific, TFS, Uppsala, Sweden) derived from the new Immu-
noCAP ISAC 103™ for simultaneous detection of IgE to 13 components 
of Dermatophagoides pteronyssinus (D.pt.) and 2 of Dermatophagoides 
farinae (D.fa.) in serum and NS.
Methods: NS were collected with both Filter Disks (FD) and Sinus 
Packs (SP) in 30 adult patients with allergic rhinitis to HDM and 29 
adult non-allergic controls. NS samples were diluted 1:20 for FD and 
1:10 for SP. Specific IgE to 13 D.pt. and 2 D.fa. components (Der p 1, 
rDer p 2, Der p 4, rDer p 5, rDer p 7, rDer p 10, rDer p 11, rDer p 14, 
rDer p 15, rDer p 18, rDer p 21, rDer p 23, clone 16; Der f 1 and Der f 2) 
were measured with the microarray both in serum (cut-off ≥ 0.10 ISAC 
standardized units [ISU]) and in NS. In NS the cut-off for IgE positivity 
needs to be determined. Hence, several analytical cut-off levels were 
tested (final cut-off reported below). Sensitivity and specificity of IgE 
tests in NS were calculated using the results of IgE tests in serum as a 
reference.
Results: With the microarray, the best balance of sensitivity and speci-
ficity was achieved with a cut-off of ≥0.03 ISU in the diluted NS. With 
this cut-off, nasal IgE to major allergen molecules (nDer p 1, nDer f 1, 
rDer p 2, rDer f 2, rDer p 23) identified the mite-allergic patients with 
90% sensitivity and 100% specificity.
Among the mite allergic subjects, prevalences of IgE positivity to 13 of 
the 15 examined components were similar in serum and NS: 83–97% 
for Der p 2 and Der f 2; 70–87% for Der p 23; 20–33% for Der p 5 and 
Der p 7; and 0–23% for all others. IgE to Der p 1 and Der f 1 were 
detected more frequent in serum (80–83%) than in NS (37–60%).
Among the non-allergic controls, no IgE to the components was 
detected in sera and NS, with the exception of IgE to Der p 5 that was 
detected (= 0.03 ISU) in 4 controls but only in their SP samples.
Conclusions: An ISAC-derived microarray technique detected nasal 
IgE to major allergen molecules D.pt. and D.fa (nDer p 1, nDer f 1, rDer 
p 2, rDer f 2, rDer p 23) identifying the mite-allergic patients with 90% 
sensitivity and 100% specificity when referred to serum. These promis-
ing findings need confirmation in larger studies (Table 1).
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Table 1  Prediction of house dust mite (HDM) allergy and serum IgE responses by testing IgE in nasal secretions in 30 HDM allergic patients 
and 29 healthy controls
Sensitivity Specificity PPV NPV Accuracy LR+ LR−
% (95% CI)† % (95% CI)† % (95% CI)† % (95% CI)† %
Filter disk
 ANY major 
molecules°
90 (73–98) 100 (83–100) 100 (82–100) 91 (75–98) 95 ∞ 0.1
  nDer p 1 46 (26–66) 100 (85–100) 100 (62–100) 73 (58–85) 78 ∞ 0.5
  nDer f 1 68 (46–85) 100 (85–100) 100 (73–100) 81 (66–91) 86 ∞ 0.3
  rDer p 2 90 (73–98) 100 (83–100) 100 (81–100) 91 (76–98) 95 ∞ 0.1
  rDer f 2 90 (73–98) 100 (83–100) 100 (81–100) 91 (76–98) 95 ∞ 0.1
  rDer p 23 81 (61–93) 100 (85–100) 100 (77–100) 87 (72–96) 92 ∞ 0.2
 OTHER molecules
  rDer p 4 0 (0–53) 98 (90–100) 0 (0–99) 88 (77–95) 86 0.0 1.0
  rDer p 5 80 (44–97) 100 (89–100) 100 (52–100) 96 (87–100) 97 ∞ 0.2
  rDer p 7 78 (40–97) 100 (90–100) 100 (47–100) 96 (87–100) 97 ∞ 0.2
  rDer p 21 57 (18–90) 100 (90–100) 100 (28–100) 95 (85–99) 95 ∞ 0.4
  ALL  molecules¥ 71 (63–77) 100 (99–100) 98 (93–100) 93 (91–95) 94 167.4 0.3
Sinus Pack
 ANY major 
molecules°
87 (69–96) 100 (83–100) 100 (81–100) 88 (72–97) 93 ∞ 0.1
  nDer p 1 58 (37–78) 100 (85–100) 100 (68–100) 78 (63–89) 83 ∞ 0.4
  nDer f 1 48 (28–69) 100 (85–100) 100 (64–100) 72 (57–84) 78 ∞ 0.5
  rDer p 2 86 (68–96) 100 (83–100) 100 (80–100) 88 (73–97) 93 ∞ 0.1
  rDer f 2 86 (68–96) 100 (83–100) 100 (80–100) 88 (73–97) 93 ∞ 0.1
  rDer p 23 81 (61–93) 100 (85–100) 100 (77–100) 87 (72–96) 92 ∞ 0.2
 OTHER molecules
  rDer p 4 14 (0–58) 98 (90–100) 50 (1–99) 89 (78–96) 88 7.4 0.9
  rDer p 5 70 (35–93) 90 (78–97) 58 (28–85) 94 (82–99) 86 6.9 0.3
  rDer p 7 67 (30–93) 100 (90–100) 100 (42–100) 94 (84–99) 95 ∞ 0.3
  rDer p 21 57 (18–90) 100 (90–100) 100 (28–100) 95 (85–99) 95 ∞ 0.4
  ALL  molecules¥ 68 (60–75) 99 (98–100) 95 (90–98) 93 (91–94) 94 80.3 0.3
† Exact binomial confidence limits (95% CI) for test sensitivity, specificity, PPV (positive predictive value); NPV (negative predictive value), 
LR + (positive likelihood ratio), LR- (negative likelihood ratio)
° Outcomes referred to at least one of the major allergen molecules (nDer p 1, nDer f 1, rDer p 2, rDer f 2, rDer p 23)
¥ Including outcomes of rDer p 10, rDer p 11, rDer p 14, rDer p 15, Clone 16, rDer p 18, all characterized by a low positive sample size (n < 5)
Keywords: Allergen Molecules, Allergic Rhinitis, House Dust Mite 
Allergy, Immunoglobulin E, Nasal Secretions
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parameters in 971 adults
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Introduction: There is a lack of published studies about the associa-
tion between  rhinomanometry and spirometry results. Some studies 
have shown a moderate correlation between spirometry parameters 
and other nasal objective measures such as Peak Nasal Inspiratory 
Flow (PNIF). We aimed to study the correlation between rhinomanom-
etry and spirometry parameters.
Methods: We included all adults (age ≥ 18 years) who performed rhi-
nomanometry and spirometry consecutively on the same day, at CUF 
Porto - Instituto and Hospital from November 2010 to July 2016. When 
more than one rhinomanometry was performed, only the first one was 
included in the analysis. We included gender, age, height, rhinoma-
nometry parameters (inspiratory and expiratory total nasal airflow, 
inspiratory (RAARi) and expiratory (RAARe) mean airflow resistance at 
a sample pressure of 150 Pa and side ratio) and spirometric parame-
ters (forced vital capacity (FVC), forced expiratory volume in 1 s  (FEV1), 
mid-flow rate/forced expiratory flow at 25–75% of FVC (FEF25-75) and 
 FEV1/FVC). Pearson’s correlation was used to evaluate unadjusted cor-
relations and partial correlations were used to adjust parameters for 
age, gender and height.
Results: A total of 971 adults were included, 623 (64%) females, with 
a mean (sd) height of 166.0 (9.0) cm and age of 38.3 (14.1) years 
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(min–max: 18–80). Correlations between spirometry and rhinoma-
nometry variables are presented in Table 1. The correlations between 
 FEV1/FVC and either inspiratory total nasal airflow or mean RAARi, 
were the only ones with statistical significance (r = −0.083, p = 0.016 
and r =  0.011, p =  0.039, respectively). After adjusting for age, gen-
der and height, no statistically significant associations were found 
between the parameters.
Table 1 Results
FVC (%) p FEV1 
(%)
p FEV1/
FVC (%)
p MEF25-
75 (%)
p
Insp total 
nasal 
airflow 
(ml/s)
−0.027 0.575 0.017 0.615 −0.083 0.016 −0.008 0.808
Exp total 
nasal 
airflow 
(ml/s)
0.032 0.359 0.052 0.131 −0.055 0.116 0.047 0.173
Mean 
RAARi 
(kPa*s/L)
0.092 0.880 −0.027 0.424 0.011 0.039 −0.047 0.160
Mean 
RAARe 
(kPa*s/L)
−0.006 0.862 −0.044 0.186 −0.012 0.731 −0.057 0.087
Side ratio −0.032 0.341 −0.046 0.165 −0.023 0.495 −0.023 0.487
Bold formatting equals the values with statistical significance
Conclusions: Rhinomanometry and spirometry parameters were not 
significantly correlated after adjustment to confounders, which sug-
gests that rhinomanometry measurements are not influenced by res-
piratory capacity measured with spirometry, contrary to PNIF. This may 
be advantageous, especially in patients with low respiratory functional 
capacity.
Keywords: Rhinomanometry, Spirometry
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Introduction: The aims of this study were (i) to characterise patients 
with persistent allergic rhinitis (PER) prescribed Meda Pharma’s AzeFlu 
(MP-AzeFlu; a novel formulation of azelastine hydrochloride, flutica-
sone propionate and excipients in a single spray) in real-life in Austria, 
Ireland and Sweden and (ii) to quantify the personal symptomatic bur-
den of PER in these countries prior to MP-AzeFlu prescription.
Methods: 428 patients (≥12  years old) with moderate-to-severe PER 
were recruited into 3, prospective, non-interventional studies car-
ried out in Austria (n = 214), Ireland (n = 53) and Sweden (n = 161). 
MP-AzeFlu was prescribed according to label. Information was gath-
ered on patient demographics, AR phenotype, allergen sensitization, 
symptomatology, previous AR treatments in the last year (prior to MP-
AzeFlu prescription) and reason for MP-AzeFlu prescription. Data for all 
countries are pooled.
Results: Classified traditionally, slightly more patients had both 
seasonal AR (SAR) and perennial AR (PAR) (n  =  254; 59.3%) vs. PAR 
alone (n  =  174; 40.7%). Sensitization to house dust mite predomi-
nated (n  =  261; 61.0%), followed by animal dander, and at least 
50.5% (n = 216) were poly-sensitized. Prior to MP-AzeFlu prescription 
patients reported troublesome symptoms (n  =  268; 62.6%), impair-
ment of daily activities (n = 238; 55.6%), sleep disturbance (n = 235; 
54.9) and impairment of school/work (n  =  177; 41.4%). Congestion 
was considered the most bothersome symptom by most patients 
(n =  254; 59.3%). The most frequent reason for MP-AzeFlu prescrip-
tion was that other therapies were not sufficient in the past (n = 299; 
69.9%) or not sufficient to treat acute symptoms (n = 87; 20.3%). Most 
of these PER patients were previously treated with oral antihistamines 
(n = 274; 64.0%), intranasal corticosteroids (n = 236; 55.1%) or intra-
nasal anti-histamines (n  =  97; 22.7%). 59.3% (n  =  254) of patients 
reported using ≥2 AR therapies in the past year, but 9.6% (n  =  41) 
reported using no AR therapy at all.
Conclusions: Many patients in Europe live with uncontrolled persis-
tent disease despite treatment with mono- and multiple therapies. A 
more effective treatment option, like MP-AzeFlu, should improve AR 
control and reduce the number of patients requiring immunotherapy.
Keywords: MP-AzeFlu, Dymista, Azelastine, Fluticasone Propionate
*MP-AzeFlu, a registered trademark of Meda AB, is marketed in the U.S. 
as  Dymista®, a registered trademark of Meda Pharma Inc., both Mylan 
Companies.
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Introduction: Prior methods used for measuring nasal specific IgE 
(NsIgE) in local allergic rhinitis (LAR) have shown a variable sensitivity: 
22% for D. Pteronyssinus (DP) using the Greiff/Grünberg method and 
lower with Naclerio method. In this study a novel method of detection 
of NsIgE in patients with confirmed LAR to DP was evaluated.
Methods: Sixteen LAR (positive nasal allergen provocation test to DP 
(NAPT-DP), negative skin testing/sIgE to DP), 10 allergic rhinitis (AR) as 
positive control (positive NAPT-DP and skin testing/sIgE to DP), and 
12 healthy controls as negative control (negative NAPT-DP and skin 
testing/sIgE to DP) were recruited. DP-ImmunoCAP® solid phase was 
applied directly in the lower turbinate of each nostril for 10 min before 
and 24  h after NAPT-DP and analyzed following the manufacturer´s 
instructions. ROC curves were performed to obtain the optimal cut-off 
point of nasal sIgE value to calculate sensitivity (S) and specificity (SP), 
and outcomes were compared with NAPT-DP result (gold standard 
test). Study was approved by local ethics committee.
Results: All LAR and AR subjects had a positive response to NAPT-DP, 
and none in the healthy control group. At 24  h after NAPT-DP, mean 
NsIgE values were 0.119 kU/L in LAR, 1.600 kU/L in AR and 0.115 
kU/L in healthy controls. ROC curves using NsIgE values obtained 
24 h after NAPT-DP were performed. In LAR subjects, the area under 
the curve (AUC) was 0.7277, p = 0.0054. The optimal cut-off point to 
discriminate LAR subjects from controls was 0.135 kU/L, obtaining a 
S = 20.31% and SP = 88.09%. In AR (positive control group) the AUC 
was 0.9798, p ≤ 0.0001, and the optimal cut-off point was 0.170 kU/L 
with S = 95% and SP = 100%.
Conclusions: Measurement of NsIgE by direct application of DP-Immu-
noCAP® in LAR shows similar sensitivity to other methods and good 
specificity, with the advantage of being non-invasive, easier to perform 
and faster. Funded by Institute of Health “Carlos III” (Ministry of Econ-
omy and Competitiveness) RETICS ARADyAL (RD16/0006/0001),  FIS 
PI14/00864 and Consejería de Salud PI-0346-2016.
Keywords: IgE, Local Allergic Rhinitis, Nasal
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Introduction: Most allergic rhinitis (AR) patients attending clinic have 
moderate/severe persistent disease and frequently report reduced 
sleep quality. Meda Pharma’s AzeFlu (MP-AzeFlu) comprises intranasal 
azelastine hydrochloride, fluticasone propionate and a novel formula-
tion, in a single device. Its real-life effectiveness has been established 
in AR during 14 days. However, its impact on sleep quality is unknown. 
This study assessed the impact of MP-AzeFlu on sleep quality when 
used in routine clinical practice by patients with persistent AR (PER).
Methods: 428 patients (≥12  years old) with moderate-to-severe PER 
were recruited into 3, prospective, non-interventional studies carried 
out in Austria (n = 214), Ireland (n = 53) and Sweden (n = 161). MP-
AzeFlu was prescribed according to its summary of product character-
istics. Patients assessed their sleep quality (7-days reflective) on days 7, 
14, 21, 28, 35 and 42 using a 5-point scale from ‘very good’ to ‘very bad’.
Results: Many patients in each country reported sleep disturbance prior 
to MP-AzeFlu prescription: n = 112 (52.3%) in Austria; n = 41 (77.4%) in 
Ireland; n = 82 (50.9%) in Sweden. MP-AzeFlu treatment (1 spray/nostril 
bd; daily doses:AZE = 548 μg;FP = 200 μg) was associated with improved 
sleep quality, evidenced by an increase in the proportion of patients 
reporting ‘very good’ and ‘good’ quality sleep in the first 28 days of treat-
ment, and a corresponding reduction in the proportion of patients 
reporting ‘bad’ or ‘very bad’ sleep quality. Sleep quality improved at each 
assessed time point (Table 1). Improved sleep quality occurred irrespec-
tive of phenotype (when classified traditionally)—in those with perennial 
AR (PAR) only and in those with both PAR & seasonal AR.
Table 1  Results
Austria† 
(n ≤ 214)
Ireland 
(n ≤ 53)
Sweden† 
(n ≤ 161)
Pooled† 
(n ≤ 428)
Day 0 
(%)
Day 28 
(%)
Day 0 
(%)
Day 28 
(%)
Day 0 
(%)
Day 28 
(%)
Day 0 
(%)
Day 28 
(%)
Very 
good
2.4 35.3 0.0 24.5 3.7 15.7 2.6 26.5
Good 25.1 44.6 24.5 50.9 28.6 44.4 26.4 46.0
Fair 36.5 17.3 32.1 15.1 34.2 25.9 35.1 20.1
Bad 28.0 2.2 32.1 5.7 27.3 12.0 28.3 6.4
Very 
bad
8.1 0.7 9.4 0.0 6.2 1.9 7.5 1.0
†   % without missing values
*MP-AzeFlu, a registered trademark of Meda AB, is marketed in 
the U.S. as  Dymista®, a registered trademark of Meda Pharma Inc., 
both Mylan Companies.
Character count: 2352 (limit = 2500).
Conclusions: MP-AzeFlu improves sleep quality in patients with mod-
erate-to-severe PER in a real-world pan-European setting.
Keywords: Dymista, MP-AzeFlu, Azelastine, Fluticasone, Rhinitis
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Introduction: Infrared thermography is a  diagnostic tool in more 
medical  disciplines.  It detects temperature changes in the infra-
red spectrum range and was originally designed to test the heat-
ing qualities of buildings. Potential benefits in allergology and ENT 
are not widely evaluated. We asked if this method can give us an 
objective information about a patient during nasal provocation 
test.
Methods: As it is difficult to detect always the same point in the face 
during repeating measurements, a bounding box to detect the face of 
a patient was designed.
Forehead, nasal, cheek and chin facial areas were defined.
Results: We present one example of our software in the evaluation 
of facial infrared thermography. This method detects temperature 
changes in different areas of the face. The nasal area was the most sen-
sitive one in the detection of temperature change during nasal provo-
cation test followed by the cheek area.
Conclusions: Facial infrared thermography might be- besides other 
important parametres like nasal symptome score and active anterior 
rhinomanometry- an objective, non- invasive and feasible tool in the 
assessment of allergic response during nasal provocation test.
Keywords: Infrared Thermography, Nasal Provocation, Bounding Box
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Introduction: Condyloma acuminatum is a venereal diasese transmit-
ted by the human papillomavirus (HPV). Generally, it is a benign entity 
but carcinomatous change has been reported in anogenital area. 
The malignant transformation is associated with the immunocom-
promised status,especially HIV. Condyloma acuminatum is uncom-
monly identified in the nasal cavity, the malignant transformation is 
extremely rare.
Methods: A mid-aged patient with diabetes mellitus and psoriasis 
had suffered from progressive right nasal obstruction with epistaxis 
for six months. Physical examination revealed a cauliflower-like lesion 
over the right nasal vestibule, expanding to the septum. Due to this 
patient had history of penile condyloma acuminatum, biopsy was 
done and sent hc2 high-risk-HPV DNA testing. The results was com-
patible with condyloma acuminatum and negative for high-risk-HPV 
infection.
Results: Eradication surgery was performed. Necrotic tissue with pus 
content was buried in the lesion. This mass was completely excised 
eventually. The formal histopathology reported condyloma acumina-
tum with focal invasive  squamous cell carcinoma. We suggested this 
patient receiving adjuvant radiotherapy or re-operation because there 
was no planed safe margin in advance, and the examinations for HIV 
and syphilis were also advised. But the patient refused and lost of fol-
low-up thereafter.
Conclusions: Human papillomavirus types 16 and 18 are found in 
up to 90% of patients with cervical carcinoma, however HPV type 
6 and HPV type 11 are the main factor in developing giant condy-
loma acuminatum, which is reported 56% incidence of malignant 
transformation. Abscesses and fistulas are more common in lesions 
as described in our case. Immunosuppression, coexisting HIV infec-
tion, and unhygienic conditions play a role in malignant transforma-
tion, therefore AIDS togethers with other venereal diseases should 
be examined. Electrocautery or laser total excision could be applied 
for treatment. Non-resectable lesions, radiotherapy could be applied 
either alone or along with chemotherapy. In conclusion, condyloma 
acuminatum with invasive squamous cell carcinoma is rarely found in 
the nasal cavity, more cases should be obtained for more comprehen-
sive understanding.
Keywords: Condyloma Acuminatum, Immunocompromised
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Introduction: One of the most common problems presenting among 
physicians are rhinitis symptoms. Challenges in the diagnosis results 
from the factor that differential diagnosis is extensive and sometimes 
symptoms of allergic, nonallergic, and mixed rhinitis are often indistin-
guishable. Searching in the literature there is a clear consensus on the 
classification but is difficult to found one that include and ordered all 
the different etiologies. It is also difficult to found an specific diagno-
sis algorithm for these diseases.
Methods: After checking over and try to reunite different consensus 
made in allergy an ENT for classification and diagnosis of rhinitis we 
propose Tables 1, 2 with both of these sections.
Results
Table 1 Classification of Rhinitis
RHINITIS
ALLERGIC NON ALLERGIC 
Allergic Rhinitis
(systemic athopy )
Local Allergic Rhinitis
(without systemic athopy)
Mixed rhinitis Infectious Non infectious
INFLAMATORIES
R. Eosinophilic
Polyps
R. Granulomatous
R. Primary atrophic
Mastocitosytosis
NON INFLAMATORIES
R. Colinérgic
R. Drugs
R. Hormonal
R. Structural
R. Irritative
R. Emotional
R. Senile
Table 2 Diagnosis algorithm for Rhinitis
ACUTE
Infectious symptoms
Anterior rhinorrhea ,  stuffiness, 
sneezing,  itchy nose
+
Ocular symptoms +/- asthma
(PROBABLY ALLERGIC RHINITIS ) ACUTE RHINOSINUSITIS 
BACTERIAN RHINITIS 
VIRAL RHINITIS 
PresentAbsent
Post nasal drip
Mucopurulent rhinorrhea
Skin prick tests SPT 
(  If negative : IgE ) 
SPT ( - ) IgE ( + ) SPT ( +) SPT ( - ) IgE ( - )
ALLERGY 
In relation with :
allergens
Search for
other etiology
ALLERGIC
RHINITIS 
In relation with :
work
Nasal 
Provocation
Nasal 
Provocation
In relation with
allergens
In relation with
work
NON ALLERGIC
OCUPATIONAL
RHINITIS 
LOCAL
RHINITIS 
ALLERGIC
OCUPATIONAL
RHINITIS 
CHRONIC
Nasal Obstruction
+/- Hyposmia
+/- Post nasal drip
ENDOSCOPY
Nasal structural abnormalities
YES NO 
POLYPOSIS
ANATOMIC DEFECTS
ATROPHIC RHINITIS
GRANULOMATOUS
(Confirm with TAC, 
RM, Biopsy)
Anterior rhinorrhea ,  stuffiness, 
sneezing,  itchy nose
DRUGS 
HORMONAL
EMOTIONAL
SENILE
GUSTATORY  
Nasal Provocation
( + )  
Relation with external
agents
VASMOTOR
RHINITIS 
( - )   ( + ) ( + )  
NO YES 
NARES
Mastocytosis
( - )  
NO 
Byopsy
Culture
( - )   
Post nasal drip
Mucopurulent
rhinorrhea
CHRONIC
RHINOSINUSITIS 
Conclusions: When approaching rhinitis, diagnostic challenge is to 
determine the etiology, specifically whether it is allergic, nonallergic, 
or perhaps an overlap of both conditions.
With these proposal tables it could be more easy to differentiate and 
lead to a correct diagnosis.
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Introduction: Most allergic rhinitis (AR) patients attending clinic 
have moderate/severe persistent disease. Meda Pharma’s AzeFlu 
(MP-AzeFlu) comprises intranasal azelastine hydrochloride, flutica-
sone propionate and a novel formulation, in a single device. Its real-
life effectiveness has been established in AR during 14  days, but its 
effectiveness in those with persistent AR (PER) over the longer term is 
unknown. We assessed the effectiveness of MP-AzeFlu in routine clini-
cal practice in PER patients, using the ARIA-endorsed language of AR 
control (i.e. visual analogue scale (VAS)). A VAS score cut-off of 50 mm 
is recommended to assess control and guide treatment decisions.
Methods: 428 patients (≥12 yrs old) with moderate/severe PER were 
recruited into 3, prospective, non-interventional studies in Austria 
(n = 214), Ireland (n = 53) and Sweden (n = 161). MP-AzeFlu was pre-
scribed according to label. Patients assessed symptom severity using a 
VAS from 0 mm (not at all bothersome) to 100 mm (very bothersome) 
in the AM prior to MP-AzeFlu use, on Days 0, 1, 3, 7, 14, 21, 28, 35 and 
42. An endoscopy was performed in the Irish study on Days 0 and 
28. Symptoms of ‘oedema’, ‘discharge’ and ‘redness’ were scored on a 
3-point scale for both nostrils (max score = 12).
Results: Patients treated with MP-AzeFlu (1 spray/nostril bd; daily 
doses: AZE  =  548  μg;FP  =  200  μg) had a VAS score reduction from 
59.0 mm (SD 25.0) at Day 0 to 28.8 mm (SD 23.2) at Day 28 (p < 0.0001) 
and 23.2 mm (SD 21.5) on Day 42 (p < 0.0001), a reduction of 35.8 mm. 
This reduction was rapid, with statistical significance vs baseline noted 
from Day 1 (p  <  0.0001), and was consistent irrespective of pheno-
type, patient age, and disease severity. On average MP-AzeFlu-treated 
patients achieved the 50  mm VAS score cut-off before Day 3. Total 
endoscopy score reduced from 7.5 (SD 3.1) at baseline to 3.5 (SD 2.5) 
at Day 28. The % of patients with severe oedema reduced from 53.1% 
at baseline to 3.8% at Day 28. A similar reduction in the incidence of 
thick/mucusy discharge (28.3–4.8%) and severe redness (34.9–0%) was 
also observed.
Conclusions: MP-AzeFlu provides effective and rapid PER control in a 
real-world pan-European setting assessed by VAS. Symptom improve-
ment was noted from Day 1, sustained for 42 days and was associated 
with improvement in mucosal appearance after 28 days.
Keywords: MP-AzeFlu, Dymista, Azelastine, Fluticasone
*MP-AzeFlu, a registered trademark of Meda AB, is marketed in the U.S. 
as  Dymista®, a registered trademark of Meda Pharma Inc., both Mylan 
Companies.
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Introduction: MP-AzeFlu*, a novel intranasal formulation of aze-
lastine hydrochloride (AZE) and fluticasone propionate (FP), has 
demonstrated superior clinical effects compared to these drugs in 
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monotherapy in patients with allergic rhinitis and chronic rhinitis. MP-
AzeFlu has previously shown greater antiinflammatory potency than 
FP and AZE in an in vitro model of eosinophilic inflammation. Our aim 
was to compare the effect of MP-AzeFlu, FP, and AZE on antiinflamma-
tory gene transactivation and proinflammatory mediator inhibition in 
sinonasal cultured fibroblasts from nasal mucosa (NM) and chronic rhi-
nosinusitis with nasal polyps (CRSwNP).
Methods: NM and CRSwNP fibroblast cultures (n = 6) were incubated 
with serial dilutions of MP-AzeFlu (1:102–1:104) or FP or AZE (equiva-
lent dilutions) for 2 to 24  h with/without 1  ng/ml IL-1b. Glucocorti-
coid-induced leucine zipper (GILZ), mitogen-activated protein kinase 
phosphatase-1 (MKP-1), and COX-2 gene (RT-PCR) and IL-8 and GM-
CSF protein (ELISA) expression was analysed. Results are expressed as 
fold-increase or % inhibition over control (mean ± SEM).
Results: MP-AzeFlu and FP (all dilutions, P  <  0.05) and AZE (1:102, 
P  <  0.05) increased GILZ and MKP-1 gene expression in NM and 
CRSwNP fibroblasts. MP-AzeFlu (1:102) had an overadditive effect on 
GILZ expression vs FP or AZE and on MKP-1 expression vs AZE (P < 0.05) 
(Table  1). MP-AzeFlu and FP provoked a similar inhibition of IL-1b-in-
duced COX-2, IL-8, and GM-CSF in NM and CRSwNP fibroblasts (all dilu-
tions, P < 0.05) but greater than AZE, which had no inhibitory effect.
Table 1  Results
NM fibroblasts CRSwNP fibroblasts
2 h 6 h 2 h 6 h
GILZ (fold increase)
MP-AzeFlu* 
(1:102)
11.2 ± 1.1 36.5 ± 7.9 14.7 ± 4.5 31.4 ± 9.2
FP (1:102) 9.4 ± 1.3† 19.8 ± 2.4† 13.9 ± 3.8 15.3 ± 4.5†
AZE (1:102) 1.8 ± 0.1† 7.9 ± 2.8† 2.5 ± 0.8† 2.8 ± 0.9†
MKP-1 (fold increase)
MP-AzeFlu* 
(1:102)
6.5 ± 1.4 5.4 ± 1.7 7.2 ± 2.1 6.2 ± 2.4
FP (1:102) 5.4 ± 0.6 4.7 ± 1.0 5.7 ± 1.5 4.8 ± 1.6
AZE (1:102) 2.1 ± 0.3† 1.8 ± 0.6† 2.9 ± 1.0† 1.9 ± 1.3†
COX-2 IL-8 GM-CSF COX-2 IL-8 GM-CSF
Proinflammatory markers (% inhibition vs control at 24 h)
MP-
AzeFlu 
(1:102)
72.0 ± 7.1 61.5 ± 5.5 80.0 ± 5.7 91.3 ± 0.5 50.4 ± 4.3 85.6 ± 4.0
FP (1:102) 93 ± 2.4 69.1 ± 3.2 81.4 ± 4.8 96.8 ± 0.7 61.3 ± 5.6 87.5 ± 3.7
This study has been sponsored by a research grant form MYLAN – MEDA
†  p < 0.05 vs MP-AzeFlu*
* Dymista
Conclusions: The superior clinical effect of MP-AzeFlu compared to 
corticosteroid or antihistamine monotherapy may be related to the 
overadditive induction of antiinflammatory genes and the inhibition of 
proinflammatory mediators. Our findings reveal some molecular basis for 
the therapeutic benefit of MP-AzeFlu in rhinitis and potentially in CRSwNP.
Keywords: MP-AzeFlu, Azelastine, Fluticasone Propionate, GILZ
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Introduction: Epithelial barrier dysfunction plays a role in the patho-
physiology of chronic rhinosinusitis with nasal polyps (CRSwNP). Toll-
like receptors (TLRs) are thought to regulate epithelial barrier integrity, 
though its function has not been studied in CRSwNP thus far. The aim 
of this study was to investigate if TLR2 and TLR4 signaling is involved in 
regulating barrier function in CRSwNP.
Methods: Primary nasal epithelial cells from controls and CRSwNP 
patients (both n =  5) were isolated and grown at air–liquid inter-
face on transwell inserts for 21  days. Epithelial integrity was eval-
uated by measuring transepithelial electrical resistance (TER) 
together with the expression of occludin and zonula occludens 1. 
TLR2 and TLR4 expression was evaluated using qRT-PCR. Primary 
nasal epithelial cells were stimulated with Staphylococcus aureus 
enterotoxin B (SEB) for 4  h and TER was evaluated. In vitro, TLR2 
and TLR4 signaling was blocked to evaluate the contribution to 
barrier dysfunction. In vivo, wild type and  TLR4−/− transgenic mice 
were used to study the role of TLR activation by SEB in increasing 
mucosal permeability for FD4.
Results: TER of CRSwNP cultures was significantly decreased com-
pared to controls, which was associated with decreased expression of 
occludin. Stimulation with SEB significantly decreased TER in CRSwNP 
cultures associated with decreased occludin, and had no effect in 
control cultures. TLR2 and TLR4 expression was elevated in CRSwNP, 
which could explain the differential SEB response. Moreover, occludin 
levels correlated inversely with TLR4 expression in CRSwNP. Antago-
nizing TLR signaling prevented SEB-induced decrease in TER in  vitro. 
In vivo, SEB increased mucosal permeability for FD4 in wild type mice 
by affecting the expression of occludin. No increased FD4 permeability 
nor decreased expression of occludin was found in  TLR4−/− transgenic 
mice.
Conclusions: TLR4 expression is increased in CRSwNP and correlated 
inversely with occludin levels. TLR4 seems a key factor in regulating 
barrier integrity in CRSwNP.
Keywords: TLR4; CRSwNP; Epithelial Integrity; Tight Junction
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Introduction: T-helper 17 (Th17) cells represent a distinct T cell linage, 
involved in the host defence against extracellular pathogens. There 
have been limited studies of a Th17 mediated inflammatory response 
in chronic rhinosinusitis patients. We aimed to study Th17 responses 
in chronic rhinosinusitis with and without nasal polyps (CRSwNP and 
CRSsNP respectively) including stimulation with Staphylococcus aureus 
enterotoxin B (SEB).
Methods: In total, 31 patients were included within the study. Nasal 
polyp, CRSsNP sinonasal mucosa and control mucosa was harvested at 
the time of surgery. Th17 cytokine gene expression was assessed using 
real time quantitative polymerase chain reaction (RT-qPCR). In addi-
tion, nasal polyp and control tissues were cultured with SEB for 24 h 
using an ex vivo nasal explant model, prior to cytokine analysis using 
RT-qPCR and Luminex.
Results: IL-17A gene expression was significantly upregulated in 
CRSsNP sinonasal mucosa compared to nasal polyps (p  <  0.05) and 
control mucosa (p  <  0.01). Upon stimulation with SEB, IL-17A gene 
expression and protein production was significantly upregulated 
(p < 0.05) within nasal polyps.
Conclusions: This study demonstrates a Th17 response in CRSsNP 
sinonasal mucosa, and in nasal polyps when stimulated with SEB. 
These results highlight the likely role of bacteria and their toxins in 
driving the inflammatory response in CRS, resulting in disease resist-
ance and long term chronicity.
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Introduction: We have previously shown that VEGF is overexpressed 
in the epithelium of hyperplastic nasal polyps in patients with chronic 
rhinosinusitis with nasal polyposis (CRSwNP). We hypothesized that 
the HIF family of transcription factors function to regulate this process.
Methods: We used human primary nasal epithelial cells grown in sub-
merged culture (PNEC) and whole human polyp tissue in air liquid 
interface culture to examine to examine HIF and VEGF expression by 
immunohistochemistry, flow cytometry and realtime PCR analysis. 
Function was assessed by exposure to known pharmacologic inhibi-
tor digoxin and specific siRNA knockdown of HIF on cell growth and 
apoptosis by DNA binding assay of PNEC and TUNEL assay of polyp tis-
sue, respectively.
Results: We now report that the HIF family of transcription factors, 
both HIF1-alpha (HIF1α) and HIF2-alpha (HIF2α), which known regula-
tors of expression of VEGF, are highly expressed in PNEC from CRSwNP 
subjects, as compared to normal control subjects when analyzed by 
flow cytometry of PNEC and immunohistochemistry of sinonasal sur-
gical tissue. PNEC from CRSwNP patients express high constitutive 
levels of mRNA of HIF1α and HIF2α. Inhibition of HIF1α by cardiac 
glycoside digoxin results in 65% inhibition of PNEC growth rates ana-
lyzed by DNA binding assay (p < 0.001, n = 5). Further studies show 
that siRNA knockdown of HIF1α results in inhibition of VEGF mRNA 
expression by 75% (p < 0.01, n = 3) and subsequent 55% inhibition 
of PNEC growth rate as measured by DNA binding assay (p  <  0.01, 
n =  3). Exposure of whole human nasal polyps in ex  vivo culture to 
HIF1α inhibitor digoxin or VEGF co-receptor inhibitor anti-neuropi-
lin1 antibody results in 90% (p < 0.01, n = 5) and twofold (p < 0.005, 
n  =  5) increase in apoptosis respectively of PNEC as assessed by 
TUNEL assay.
Conclusions: Collectively, these data indicate that HIF regulates VEGF 
in promoting hyperplastic nasal epithelial cell growth and survival 
observed in CRSwNP.
Keywords: Nasal Polyposis, Epithelial Cell Growth, VEGF, HIF
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Introduction: Two major clinical phenotypes of chronic rhinosinusitis 
(CRS), with (CRSwNP) and without nasal polyps (CRSsNP) may show 
different regulation of inflammation, interplay between T cell subsets, 
remodelling, response to microbiome and association with predispos-
ing comorbidities, like allergy, asthma and aspirin intolerance. IL-7 
and IL-15 belong to common gamma chain cytokines, and are essen-
tially involved in T cell homeostasis and proliferation. Several papers 
indicated that they might be involved in the immune response in 
asthma, however, their role in CRS was not evaluated. Our aim was to 
analyze interaction between IL-7 and IL-15 related to phenotypes and 
comorbidities.
Methods: The study included 50 patients(both gender, age 
18–60 years, 32 with CRSsNP, and 18 with CRSwNP), with CRS accord-
ing to the EPOS criteria, who were submitted to endoscopic sinus 
surgery. Ethmoid sinus mucosa or nasal polyps were collected at sur-
gery and immediately tissue homogenates were prepared and incu-
bated with protease inhibitor. Assays (R&D System, Quantikine ELISA, 
UK) for interleukins IL-4, IL-5, IL-7, IL-15 and for interferon gamma 
(IFN-γ) employs the quantitative sandwich enzyme immunoassay 
technique. Tissue homogenates (n = 70) were analysed according to 
the manufacurer’s instructions (29 from non-allergic CRSsNP, 17 from 
allergic asthma patients, 11 from non-allergic asthma, 9 from allergic 
non-asthmatic CRSsNP and 4 from aspirin intolerant CRSwNP). Polyp 
and ethmoid sinus mucosa samples were taken in CRSwNP, and only 
ethmoid sinus mucosa from patients with CRSsNP, respectively, from 
the worse side according to imaging.
Results: Results. IL-5 was significantly higher (mean 38.69 vs. 9.47 pg/
mL respectively), but IL-7 (0.1397 vs. 0.2638 pg/mL, respectively), and 
IFN-γ (22.44 vs. 41.71 pg/mL, respectively) significantly lower in sam-
ples from CRSwNP, and these differences were also significant when 
asthmatic were compared to non-asthmatic, irrespective of pheno-
type and sensitization. Interestingly, IFN-γ was significantly higher in 
patients with allergic sensitization, while IL-4 was significantly higher 
in patients with ASA intolerance. IL-15 significantly correlated with 
IL-7 (rho 0.44), IL-4 (rho 0.31) and IFN-γ significantly with IL-4 (rho 
0.51).
Conclusions: IL-7 and IL-15 are significantly upregulated in CRSsNP 
compared to CRSwNP and in non-asthmatics compared to asthmatics.
Keywords: IL-7, IL-15, Chronic Rhinosinusitis, Nasal Polyps, T Cell 
Subset
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Introduction: Acute and chronic rhinosinusitis affect everyone several 
times per year and 11% of the EU population, respectively.
Methods: Double-blind randomized placebo-controlled trials.
Results: Recently, the herbal drug BNO 1016 showed evidence for 
a significant and clinically relevant reduction of symptoms and 
increase of quality of life. In an analysis of pooled data of two similar 
randomized placebo-controlled clinical trials including 589 patients, 
the Major Symptom Score (MSS) improved from 10.02  ±  1.61 to 
2.47  ±  2.55 for BNO 1016 and from 9.87  ±  1.52 to 3.63  ±  3.63 for 
placebo; the difference between treatment groups at end of therapy 
(1.16 score point ±  [SD]) was statistically significant in favor of BNO 
1016 (p  <  0.0001); patient-assessed quality of life also improved sig-
nificantly (p = 0.0015) versus placebo. The results were confirmed by 
ultrasonography. In summary, the herbal dry extract BNO 1016 is effi-
cacious and well tolerated in patients with acute viral rhinosinusitis.
The objective of a recent clinical trial therefore was to assess the effi-
cacy, safety and tolerability of dry extract BNO 1016 in patients with 
chronic rhinosinusitis. 927 patients suffering from chronic rhinosinusitis 
(>12 weeks and 6 ≤ MSS ≤ 12) were enrolled in a randomised placebo-
controlled trial with a treatment period of 12 weeks. The primary end-
point was the mean Major Symptom Score (MSS) over week 8 and week 
12 compared to placebo. Secondary endpoint included further MSS 
related calculations and responder rates over time. Finally, safety and 
tolerability were evaluated. Although the results of the secondary end-
points showed a clear trend towards superior efficacy, BNO 1016 was 
not superior over placebo regarding the primary endpoint. Additional 
post hoc sensitivity analyses in patients with a baseline MSS ≥ 10, dura-
tion of disease > 1 year and diagnosed by specialists in otorhinolaryn-
gology indicated that those patients significantly benefited from BNO 
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1016. Therapy was superior for the primary endpoint analysis. Patients 
were less impaired with respect to work and daily activities. A good 
safety and tolerability of BNO 1016 was assured in all patients.
Conclusions: Rhinosinusitis, a frequent cause of disease and associ-
ated sequalae, still remains a challenge for treatment. BNO 1016 can 
safely be administered in patients with acute and chronic rhinosinusi-
tis and offers a suitable treatment option.
Keywords: Acute Rhinosinusitis, Chronic Rhinosinusitis, Phytotherapy, 
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Introduction: Aspirin exacerbated respiratory disease (AERD) is 
characterized by acute aspirin-triggered respiratory distress, chronic 
asthma and nasal polyps that are often refractory to steroid treat-
ment. AERD patients show characteristic abnormalities in lipid media-
tor (eicosanoid) metabolism and signaling, but the mechanisms that 
discriminate nasal polyp development in AERD and aspirin tolerant 
chronic rhinosinusitis with nasal polyps (AT CRSwNP) remain obscure. 
We thus compared eicosanoid profiles in nasal polyps from AERD and 
AT CRSwNP patients and analyzed the expression of factors involved in 
airway remodeling.
Methods: Nasal polyp tissues (n = 10 AT CRSwNP, n = 4 AERD) were 
obtained from patients undergoing functional sinus surgery. All 
patients were treated with systemic steroids preoperatively. Expres-
sion of eicosanoid pathway proteins and regulatory factors in nasal 
polyp tissues or healthy turbinates (n = 3) was studied by immunoflu-
orescence and immunohistochemistry followed by automated image 
analysis. Supernatants from overnight cultures of nasal polyps were 
processed and subjected to lipid mediator analysis by LC–MS/MS or 
immunoassay.
Results: Nasal polyp tissues from steroid treated AT CRSwNP and 
AERD patients expressed high levels of leukotriene (LT) biosynthetic 
enzymes (5-lipoxygenase, Leukotriene C4 synthase) despite low levels 
of infiltrating granulocytes. LT enzymes were abundant in the nasal 
polyp epithelium and in macrophages and all nasal polyp tissues 
released significant amounts of LTs. The overall eicosanoid profile was 
similar in nasal polyps from AT CRSwNP and AERD patients with a ten-
dency for increased thromboxane production by AERD tissues. In con-
trast AERD tissues expressed significantly lower levels of the enzymes 
transglutaminase 2 (TG2) and microsomal prostaglandin E2 synthase 
(mPGES-1). TG2 was particularly abundant in tissues from house dust 
mite allergic patients.
Conclusions: Our findings identify TG2 as a potential mechanism 
that discriminates nasal polyp endotypes. We further show that TG2 
expression and LT production in nasal polyp epithelium are resistant 
to steroid treatment. Thus, targeting TG2 might be promising in aller-
gic CRSwNP patients and novel strategies targeting steroid resistant 
lipid mediator abnormalities in nasal polyps are urgently needed.
Keywords: AERD, Allergy, Eicosanoids, Nasal Polyps, Transglutaminase 
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Introduction: T cell subpopulations in nasal polyps differ from periph-
eral lymphocytes in patients with CRSwNP. The direct influence of the 
nasal polypoid tissue by secretion of cytokines on the differentiation 
or activation of T cells still remains unclear. To study the effects of 
polypoid tissue on peripheral lymphocytes in  vitro, we developed a 
co-culture system with nasal polyp tissue and peripheral lymphocytes 
to directly measure these interactions. Additionally, we assessed the 
cytokine secretion by polyp tissue, which may induce T cell responses 
in this system.
Methods: Tissue and blood samples were collected from 10 patients 
undergoing nasal sinus surgery. Polypoid tissue was cultured under 
air–liquid interface conditions. Afterwards, CD3/CD28 activated PBMC 
of the same patients were added using cytokine free medium. After 
3 days, lymphocytes were separated and analyzed by multicolor flow 
cytometry. Monoculture PBMC served as control group. Additionally, 
cytokine secretion of the polyp tissue was measured using a human 
Th1/Th2/Th17 antibody array.
Results: There was a significantly higher amount of  CD4+ and CD8 + T 
cells in the co-cultured system than in PBMC alone. Terminal differenti-
ated CD8 + T cells were significantly increased, while central memory 
CD8  +  T cells significantly decreased in the co-culture. HLA-DR was 
downregulated in co-cultured CD3  +  lymphocytes. Conventional 
memory CD4 + T cells significantly increased and resting regulatory T 
cells significantly decreased in the co-cultured system. Cytokine analy-
sis showed a secretion of IL-6, GM-CSF and MIP-3.
Conclusions: It could be demonstrated that nasal polypoid tissue has 
an effect on the PBMC phenotype. The secretion of pro-inflammatory 
cytokines may play a regulatory role in this context. Interestingly, the 
clinically known downregulation of HLA-DR in CD3  +  lymphocytes 
was significantly reproducible in  vitro. The modulating effect of the 
polypoid tissue on the activation of lymphocytes must be further 
investigated in order to determinate its impact on this disease.
Keywords: Chronic Rhinosinusitis With Nasal Polyps, T Cell Subsets, 
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Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) 
is an uncommon systemic necrotizing vasculitis that affects small to 
medium sized vessels and is associated with severe asthma, allergic 
rhinitis, nasal polyposis and blood and tissue eosinophilic infiltra-
tion. Antineutrophil cytoplasmic autoantibodies (ANCA) are present 
in about 40% of cases. The presence of four or more of the above 
described findings yields a sensitivity of 85% and a specificity of 99.7% 
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for the final diagnosis of EGPA. The aim of the study was to develop a 
new diagnostic tool to support the diagnostic and prognostic work-up 
of EGPA patients with the possibility to evaluate extracellular media-
tors in nasal secretion.
Methods: Nasal secretions were gained from 40 patients of which 20 
EGPA, 10 suspected EGPA and 10 controls after positioning the cot-
ton pieces in the nasal middle meatus where they were left for 10 min. 
Subsequently the cotton pieces were put in 5 ml of saline solution and 
left in ice until processing. The liquid obtained from the squeezing of 
the cottons was centrifuged two times at 1600 RPM for 10 min. Super-
natant was frozen after first centrifugation. Trypan Blue was added 
to 10  μl of sample to calculate the number of cells and their vitality. 
Finally, 100 μl of sample with containing 1.5–2.00 × 105 cells were cen-
trifuged with Cytospin at 300 RPM for 15 min. The slides were stained 
with May Grunwald/Giemsa and cell population analysed at micro-
scope with objective oil immersion 40× of magnification. The remain-
ing cells were frozen or cultured.
Results: The mean number of cells obtained after centrifugation was 
2.00–4.08 × 106 cells/ml for EGPA patients and 6.42–8.62 × 105 cells/
ml for control group and suspected EGPA. Cytologic analysis allowed 
us to count an increase in the percentage of eosinophils in EGPA 
patients with active ENT disease and in some of the patients with a 
suspect of EGPA, where this percentage correlated with histologic evi-
dence of disease.
Conclusions: This method seems preliminarily a reliable cytologic 
examination allowing fresh cells isolation and analysis of extracellular 
mediators. Compared to the direct slither of the mucus on the surface 
of the glass, cytospin significantly reduced any dye accumulation. Fur-
ther studies are ongoing to support the described method, in order to 
confirm the cytologic diagnostic reliability to identify prognostic bio-
markers of EGPA.
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Introduction: Type I interferons (IFN-I) response has been implicated 
in the eosinophilic inflammation besides its antiviral function.  This 
study aimed to investigate the role of IFN-I response in the pathogen-
esis of eosinophilic chronic rhinosinusitis (ECRS).
Methods: The expressions of IFN-I and IFN-I receptor (IFNAR1) in 
sinonasal tissue from controls and patients with CRS with nasal polyp 
(NP) were measured using real time-PCR, ELISA, and/or immunohisto-
chemistry. The levels of CCL11/eotaxin-1, IL-5, and IL-13 in sinonasal 
tissue of human subjects were determined by ELISA. ECRS in the wild 
type (WT) and IFNAR1 knockout (Ifnar1−/−) mice was induced by intra-
nasal challenge of aspergillus protease plus ovalbumin (OVA). Stromal 
cells cultured from NP tissue were stimulated by exogenous IFN-β and 
their CCL11/eotaxin-1 production was measured by ELISA.
Results: IFN-β, IFNAR1, IL-5, IL-13, and CCL11 expressions were 
increased in NP tissues from ECRS compared with uncinated process 
mucosa from controls. IFN-β levels positively correlated with IL-13 
and CCL11 levels. The histological severity of Aspergillus protease plus 
OVA induced-ECRS was less in Ifnar1−/− than in WT mice. The levels of 
IL-4, IL-5, and CCL11 in the nasal lavage fluid of Ifnar1−/− mice were 
significantly lower than those in WT mice. The serum total IgE levels in 
Ifnar1−/− mice were also lower than those in WT mice. NP stromal cells 
produced significantly greater amount of CCL11/eotaxin-1 by concen-
tration-dependent stimulation of IFN-β.
Conclusions: Our results showed that IFN-I response was up-regulated 
in the NP tissues from ECRS, IFN-β increased CCL11/eotaxin produc-
tion in the NP stromal cell culture model, and development of ECRS 
was inhibited by deficiency in IFN-I signaling. Therefore, increased 
IFN-I response in the sinonasal mucosa may underlie in the pathogen-
esis of ECRS.
Keywords: Chronic Rhinosinusitis, Type I Interferon, Eosinophil
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Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) 
affects 4% of the total population (C.A. Akdis, 2013). The prevalence of 
CRSwNP in Russian Federation (RF) is 1.5% or 4.9 per 10,000 popula-
tion (Lopatin A, 2014). The ratio and number of neutrophils and eosin-
ophils in the vast majority of nasal polyps (NP) are diverse. According 
to the data from research neutrophilic types of adult bilateral polyps 
do occur, predominantly in Asian subjects and some populations in 
North America (Zhang N, 2006). Russia is a multiethnic country that 
separates Europe and Asia. It is of interest as a target for epidemiologi-
cal studies.
The aim was to explore the histology of NP biopsies obtained from 
operated patients with CRSwNP living in different regions of RF.
Methods: NP samples obtained from 152 patients during polypec-
tomy were assaying histologically to identify neutrophils and eosino-
phils count and ratio of eosinophils to neutrophils (ENR) in biopsies. 
There were 10–11 samples of polyp’s tissue from 15 ENT hospitals from 
different regions of the country. There was equal quantity of partici-
pants of 12 nationalites belonging to Caucasian or Mongoloid race. All 
patients completed a questionnaire including data about symptoms, 
nationality, comorbidities, atopic reactions and drug hypersensitivity.
Results: There was predominance of eosinophil’s infiltration (>90% 
of all cells) in all NP samples. There were no significance between 
clinical symptoms and NER. The NP with predominant eosinophil’s 
count (ENR median total  =  6.8) were isolated from Siberian and 
Volzhsky region habitants (Tomsk ENR  =  23.3, Irkutsk  =  9.14, Nizh-
niy Novgorod  =  11.3). There were no significant differences in ENR 
in patients of different nationalities. Moreover the predominance of 
eosinophilic infiltration in Russian (Caucasoid) were revealed in 69.5% 
of cases versus patients with other nationalities patients (83%). In 
most biopses from Russian patients ENR = 6.0 in comparison to others 
ENR = 6.9.
Conclusions: There’re some hypotheses about triggering factors of 
CRSwNP. The most popular one is the influence of microbial agents 
(C. Bachert). Probably the features of infectious and parasitic diseases 
(zoonoses, insect bites, ticks, infected fish, etc.) and climate factors are 
cause of debut of formation of polyps. Russia is excellent model for 
epidemiological studies that could reveal these factors.
Keywords: Nasal Polyp, CRSwNP, Eosinophils, Endotypes
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Introduction: Is concurrent eosinophilic oesophagitis and sinonasal 
polyposis a pure coincidence? Or, do they share common pathogen-
esis? We report a case series of four subjects with both conditions 
managed at a local allergy clinic in Adelaide, South Australia, Australia, 
highlighting certain features common to both.
Methods: N/A.
Results: All four subjects ranged from age 50 to 61 at the time of 
presentation, seeking treatment for chronic nasal symptoms, which 
were managed predominantly with intranasal corticosteroids. All 
four were asthmatic and have had intranasal surgery in the past, 
with two of them having had four surgeries to date. Results of polyp 
biopsy were not available. Peripheral eosinophilia was characteristic 
of all four, ranging from 0.6 to 1.56 ×  109. Background of atopy was 
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further evaluated with skin prick testing with aeroallergens and food 
allergens with no concordant findings noted across all four subjects. 
Nasal symptoms preceded oesophageal symptoms by 2 to 3 years. All 
subjects had oesophageal biopsy confirming eosinophilic oesophagi-
tis. Three subjects were aspirin sensitive. Aspirin or sodium salicylate 
desensitisation was tried without success. Two subjects responded 
to low salicylate diet with the remaining two not yet trialled on such. 
Three subjects responded symptomatically to montelukast.
Conclusions: Is there a single factor driving the pathomechanistic 
pathway e.g. IL-5? Nasal polyposis occurs frequently in patients with 
intolerance to salicylate acid and those with allergic fungal sinusitis. It 
has been demonstrated that IL-5 has a key role in the pathophysiol-
ogy of eosinophil dominated polyps. Additionally, adhesion molecules 
VCAM-1 is recognised to play a role in the extravasation of eosinophils 
into nasal polyps and cytokines such as IL-3, IL-4 and TNF-a can induce 
VCAM-1 expression in microvascular endothelium from the polyps. 
Future planned testing includes eosinophil activation markers on flow 
cytometry, along with serum levels of cytokines mentioned.
Further questions then arise for the management of future patients, 
especially in regards to the eosinophilic oesophagitis component. Is it 
worthwhile to have six food elimination diet based on skin prick test-
ing results, followed by a low salicylate diet? In the case where aspirin 
sensitivity is confirmed, is it worthwhile to have a direct move to low 
salicylate diet? Is it worthwhile to attempt sodium salicylate desensi-
tisation on all aspirin sensitive or dietary salicylate sensitive patients?
Keywords: Eosinophilic Oesophagitis, Sinonasal Polyposis, Eosino-
philic Disorder
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Introduction: Traditionally, Draf III procedure is considered for 
accessing the refractory pathogens inside the frontal sinus. In case 
of confined, predominantly unilateral lesions, Draf IIb procedure 
also provides wide access to the frontal sinus. This approach can be 
extended without destruction of the contralateral frontal sinus drain-
age pathway.
Methods: We report on a patient suffering from left frontal pain 
and nasal obstruction for 6  months. He received examination in our 
department, and fiberscopy revealed polyposis. Computed tomog-
raphy displayed the over-pneumatized right frontal sinus pushing 
intersinus septum toward to left side and causing narrowed left frontal 
space. We decided to performe Draf IIb.2 procedure.
Results: Once the frontal recess is identified, we started using the irri-
gated RAD curved burr (3.6 mm 55°) to remove partial anterior–supe-
rior portion of middle turbinate and frontal beak. After identifying 
intersinus septum, we removed its lower part and formed a drainage 
pathway through rightl frontal sinus. There were no sequelas and 
patient felt well during follow-up.
Conclusions: In case of confined, unilateral frontal lesions, less 
destructive, limited approaches, defined as extended Draf IIb, can 
be applied without disturbing the contralateral frontal sinus drain-
age pathway according to the literatures. Gotlib et  al. have classified 
extended Draf IIb procedure into 3 subtypes; Extended Draf IIb.2 (or 
mini-Lothrop) refers to Draf IIb procedure with removal of the lower 
intersinus septum. This technique is applicable for bilateral frontal 
lesions with one side limiting in frontal sinus or unilateral frontal sinus 
disease with intersinus septum deviation towards the lesion. It can 
minimiz destruction of the contralateral frontal sinus drainage path-
way when comparing to Draf III. The nasal septum can be kept intact 
as compared to Draf IIb.1 and Draf IIb.3 procedures.
Keywords: Draf IIb Procedure
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Introduction: Birch pollen allergic rhinitis (AR) is one of the common 
allergic diseases in Europe. Little knowledge exists on changes in nasal 
epithelial transcriptome during allergen exposure or allergen specific 
immunotherapy. The aim of this study was to evaluate the seasonal 
and immunotherapy-related alterations in nasal epithelial transcrip-
tome in subjects with or without birch pollen allergic rhinitis (AR).
Methods: The study subjects were healthy nonsmoking adults with 
or without birch pollen AR (N = 11). We used the RNA sequencing to 
demonstrate the alterations in transcriptome of study subjects. The 
whole study spanned on two years i.e. 4 seasons, where half of the AR 
patients started the immunotherapy during the second year. We used 
edgeR for differential expression analysis and R environment for fur-
ther Bioinformatics. Gene Ontology (GO) and KEGG pathway enrich-
ment was done using DAVID (Database for Annotation, Visualization, 
and Integrated Discovery).
Results: We found a significant change in gene expression of the nasal 
epithelial cells in AR patients not having the immunotherapy com-
pared to healthy controls. We found immunity related GO terms up 
or down -regulated in these patients. We also observed variations in 
biological processes of IL-2 production, cytokines production, regula-
tion of lymphocyte and leukocyte differentiation. Immunotherapy 
induced a down regulation of GO terms related to immune response 
in AR patients.
Conclusions: Birch pollen AR induces in-seasonal changes in gene 
expression. It can alter the regulation of immunity related functions 
and pathways in AR patients. Immunotherapy might normalize the 
barrier function by decreasing epithelial immune response. More 
research with larger number of samples from different populations is 
needed.
Keywords: Allergic Rhinitis, Birch Pollen, Gene Ontology, Immunother-
apy, KEGG
Oral Abstract Session 7: Allergen Immunotherapy - Hot Topics
O12 
Subcutaneous house dust mite immunotherapy is associated 
with a long‑term suppression of allergen‑induced basophil 
activation: a prospective study
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Introduction: The effect of allergen-specific immunotherapy (IT) on 
basophils remains incompletely understood. Several studies have 
shown an early suppression of basophil activation, and a few studies 
have reported long-term suppression in response to IT. These studies 
involved venom, grass, birch or cat IT. To our knowledge, no previous 
studies investigated the effect on basophil activation in the context 
of house dust mite (HDM) IT. Objectives: To study the effect of HDM IT 
on allergen-stimulated basophil activation and to evaluate its relation 
with clinical response to treatment.
Methods: Patients with HDM allergic rhinitis undergoing conven-
tional HDM subcutaneous IT (HDM SCIT, n  =  23) and patients not 
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undergoing IT (HDMA, n =  10) were studied prospectively. Basophil 
activation experiments were performed before start of IT (visit 0), half-
way initiation (visit 1), at the end of initiation (visit 2), after 4 months 
of maintenance (visit 3), and after one year of treatment (visit 4). The 
same time line was followed for the HDMA subjects. Whole blood sam-
ples were stimulated with various concentrations (0.0023–22.7 ng/ml) 
of Dermatophagoides pteronyssinus extract. Activated basophils were 
identified with flowcytometry by expression of CD63. Dose–response 
curve metrics (EC50, CD-sens, and Area Under the Curve) were deter-
mined as measures for basophil allergen-sensitivity.
Results: HDM IT induced a significant decrease of basophil activa-
tion over time (p < 0.001; change observed from visit 2, most marked 
at visit 3, maintained at visit 4). In the patients not undergoing IT no 
significant changes in basophil activation were observed (p = 0.523) 
and the difference between both groups was significant (HDM SCIT vs. 
HDMA, p = 0.005). After one year of treatment with IT, three patients 
reported “no change”, five patients “a little improvement”, six patients 
“improvement”, and nine patients “large improvement” of allergy 
symptoms. None of the patients reported worsening of symptoms. 
Within the HDM SCIT group, the change in allergen-stimulated baso-
phil activation was not correlated with the change in patient-reported 
symptom control (VAS score,  rs = 0.26, p = 0.24).
Conclusions: A long-term decrease of allergen-stimulated basophil-
activation was observed in response to treatment with house dust 
mite subcutaneous immunotherapy. The degree of change in basophil 
activation was however not associated with the degree of symptom 
improvement.
Keywords: Allergy, Rhinitis, Immunotherapy, House Dust Mite, 
Basophils
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Introduction: Allergen immunotherapy (AIT) with house dust mite 
extracts has demonstrated to be an effective treatment in patients 
with local allergic rhinitis (LAR).
The objective of this study was to evaluate the efficacy of subcutane-
ous AIT with Phleum pratense in LAR patients.
Methods: A randomized double-blind, placebo-controlled, parallel-
group (DBPCPG), phase II investigator-initiated trial was conducted 
in 56 patients with LAR to Phleum pratense. All subjects provided 
informed consent, and the Ethic Committee and Spanish Drug Agency 
approved the study. clinicaltrials.gov identifier: NCT02126111.
During the 1st year subjects were randomized to receive subcuta-
neous AIT with depigmented polymerized 100% Phleum pratense 
allergen extract (LETI, S.L.U. Tres Cantos, Madrid) or placebo. During 
the 2nd year all received AIT. Differences regarding clinical response 
(combined symptoms-medication score (CSMS), medication free days), 
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), titrated nasal 
allergen provocation test (NAPT), skin testing, serum levels of specific-
IgG4 and -IgE, and safety between groups were analyzed. Patients 
were classified as responders (increased tolerance to the allergen in 
the NAPT) and non-responders (no increased tolerance).
Results: During the 1st year AIT induced significant improvements 
compared to placebo in CSMS (1.2 ± 0.8 vs 2.6 ± 1.2, P = 0.001), num-
ber of medication free days (18.1 ± 9.8 vs 4.1 ± 3.3, P < 0.001), RQLQ 
score (1.98 ±  0.91 vs 3.67 ±  1.27, P =  0.001), and allergen tolerance 
in NAPT (0.024 ± 0.038 mcg/mL vs 0.003 ± 0.004 mcg/mL, P = 0.010) 
compared to placebo. The rate of responders was 50%, with nega-
tivization of NAPT in 19% of patients treated with AIT. During the 2nd 
year, a comparable improvement in CSMS, RQLQ and nasal allergen 
tolerance was observed in both groups. Immunotherapy was well-tol-
erated, with only six local reactions resolved without treatment.
Conclusions: Subcutaneous immunotherapy with this depigmented 
polymerized allergen extract is a safe and clinically effective treatment 
for LAR to Phleum pratense with clear improvement in disease-specific 
quality of life.
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